Idioma:

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

Ferguson, L Paige ; Gatchalian, Jovylyn ; McDermott, Matthew L ; Nakamura, Mari ; Chambers, Kendall ; Rajbhandari, Nirakar ; Lytle, Nikki K ; Rosenthal, Sara Brin ; Hamilton, Michael ; Albini, Sonia ; Wartenberg, Martin ; Zlobec, Inti ; Galván, José A ; Karamitopoulou, Eva ; Vavinskaya, Vera ; Wascher, Alexis ; Lowy, Andrew M ; Schürch, Christian M ; Puri, Pier Lorenzo ; Bruneau, Benoit G ; Hargreaves, Diana C ; Reya, Tannishtha

Nature communications, 2023-01, Vol.14 (1), p.292-292, Article 292 [Periódico revisado por pares]

England: Nature Publishing Group

Texto completo disponível

Citações Citado por

Enviar para

Título:
Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma
Autor: Ferguson, L Paige ; Gatchalian, Jovylyn ; McDermott, Matthew L ; Nakamura, Mari ; Chambers, Kendall ; Rajbhandari, Nirakar ; Lytle, Nikki K ; Rosenthal, Sara Brin ; Hamilton, Michael ; Albini, Sonia ; Wartenberg, Martin ; Zlobec, Inti ; Galván, José A ; Karamitopoulou, Eva ; Vavinskaya, Vera ; Wascher, Alexis ; Lowy, Andrew M ; Schürch, Christian M ; Puri, Pier Lorenzo ; Bruneau, Benoit G ; Hargreaves, Diana C ; Reya, Tannishtha
Assuntos: Adenocarcinoma ; Animal models ; Animals ; Cancer ; Carcinoma, Pancreatic Ductal - drug therapy ; Carcinoma, Pancreatic Ductal - genetics ; Carcinoma, Pancreatic Ductal - pathology ; Chemotherapy ; Epigenesis, Genetic ; Epigenetics ; Fatty acids ; Genetic diversity ; Humans ; Lipid metabolism ; Lipids ; Medical prognosis ; Metabolism ; Mice ; Pancreatic cancer ; Pancreatic Neoplasms ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - genetics ; Pancreatic Neoplasms - metabolism ; Stem cell transplantation ; Stem cells ; Suppressors ; SWI/SNF complex ; Therapeutic targets ; Transcription Factors - genetics ; Transcription Factors - metabolism ; Tumors
É parte de: Nature communications, 2023-01, Vol.14 (1), p.292-292, Article 292
Notas: ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Pancreatic cancer is characterized by extensive resistance to conventional therapies, making clinical management a challenge. Here we map the epigenetic dependencies of cancer stem cells, cells that preferentially evade therapy and drive progression, and identify SWI/SNF complex member SMARCD3 as a regulator of pancreatic cancer cells. Although SWI/SNF subunits often act as tumor suppressors, we show that SMARCD3 is amplified in cancer, enriched in pancreatic cancer stem cells and upregulated in the human disease. Diverse genetic mouse models of pancreatic cancer and stage-specific Smarcd3 deletion reveal that Smarcd3 loss preferentially impacts established tumors, improving survival especially in context of chemotherapy. Mechanistically, SMARCD3 acts with FOXA1 to control lipid and fatty acid metabolism, programs associated with therapy resistance and poor prognosis in cancer. These data identify SMARCD3 as an epigenetic modulator responsible for establishing the metabolic landscape in aggressive pancreatic cancer cells and a potential target for new therapies.
Editor: England: Nature Publishing Group
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Smarcd3 is an epigenetic modulator of the metabolic landscape in pancreatic ductal adenocarcinoma

England: Nature Publishing Group

Buscando em bases de dados remotas. Favor aguardar.